Rapamycin (Sirolimus) Regret, Stopping, and Restarting: What Real Users and the Evidence Say

Is there any real data on rapamycin regret?

The human trials of low-dose rapamycin in healthy people reported adverse events, blood biomarkers and health measures [2][3]. Neither measured regret, discontinuation rates or restart rates as an outcome.

What circulates as user experience is forum and social media posts. Those describe individual experiences, not how often anything happens, and the trial data are a different kind of evidence [2][3].

What the human trials actually measured

PEARL (2025). A 48-week decentralized, double-blind, placebo-controlled trial in healthy adults with normative aging; participants took placebo, 5 mg or 10 mg of compounded rapamycin once weekly [2]. The primary outcome, visceral adiposity measured by DXA, did not change (p=0.942) [2]. Adverse and serious adverse events were similar across all groups, and blood biomarkers stayed within normal ranges [2]. Lean tissue mass (p=0.013) and self-reported pain (p=0.015) improved in women taking 10 mg, and self-reported emotional well-being (p=0.023) and general health (p=0.004) improved on 5 mg [2]. The authors described low-dose intermittent rapamycin as relatively safe over 48 weeks and said efficacy is not established; the trial measured no lifespan outcome [2].

Kraig (2018). Twenty-five generally healthy adults aged 70 to 95 were randomized to 1 mg rapamycin daily or placebo; 11 rapamycin and 14 placebo participants completed at least 8 weeks [3]. Reported side effects in the rapamycin group were facial rash in one person, stomatitis in one and gastrointestinal issues in two [3]. The rapamycin group had statistically significant decreases in hemoglobin, hematocrit, red cell count, RDW, MCV and MCH [3]. That trial was a pilot of feasibility and safety in older adults, not a lifespan study [3].

Why people stop: what the label lists

The label's adverse reaction data come from kidney transplant patients, all of whom also took cyclosporine and corticosteroids in the main study, and from the LAM study, not from healthy adults on weekly dosing [1].

Discontinuation. In the LAM study, 11% of subjects discontinued because of adverse reactions, and no single reaction led to discontinuation in more than one patient on Rapamune [1]. In the kidney transplant trials, increased creatinine, hypertriglyceridemia and TTP were the reactions with a discontinuation rate above 5% [1].

Mouth sores. In the LAM study, stomatitis was among the most common adverse reactions, at 20% or more [1]. In the kidney transplant study it appeared in between 3% and 20% of patients [1].

Skin. Acne was reported in 22% of patients on 2 mg, 22% on 5 mg and 19% on placebo [1].

Lipids. Hypercholesterolemia occurred in 43% to 46% of rapamycin patients and hypertriglyceridemia in 45% to 57%, against 23% each on placebo [1]. The label says any patient given Rapamune should be monitored for hyperlipidemia, with diet, exercise and lipid-lowering agents if it is detected [1].

Blood counts. Anemia occurred in 23% on 2 mg, 33% on 5 mg and 21% on placebo; thrombocytopenia in 14%, 30% and 9% respectively [1].

The serious end of the list. The label warns of increased susceptibility to infection and possible lymphoma and other malignancies from immunosuppression, proteinuria, interstitial lung disease and non-infectious pneumonitis, fluid accumulation and impaired wound healing, male infertility with azoospermia or oligospermia, and fetal harm [1].

What the label says about drug levels and dosing

Sirolimus is extensively metabolized in the intestinal wall and liver by CYP3A4, with P-glycoprotein pumping it back into the gut, and it has a mean terminal half-life of about 62 hours (SD 16) in stable kidney transplant patients [1].

The label's dosing sections are built around reaching a target trough concentration [1]. In hepatic impairment, AUC rises 43% in mild, 94% in moderate and 189% in severe impairment, and the label reduces the maintenance dose by about one third in mild-to-moderate and one half in severe impairment [1].

The closest human immune data come from a different drug. In a 2014 trial, elderly volunteers given the mTOR inhibitor RAD001 (everolimus) had about a 20% better antibody response to influenza vaccination at relatively well-tolerated doses, and a lower percentage of CD4 and CD8 T cells expressing PD-1 [4]. Everolimus is not sirolimus, and the endpoint was vaccine response, not aging [4].

If you restart: what the label flags

Interactions. Sirolimus is a substrate of both CYP3A4 and P-glycoprotein, and the label says to avoid strong inducers such as rifampin and rifabutin and strong inhibitors such as ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin and clarithromycin [1]. It advises caution with weaker modulators, including diltiazem, verapamil, fluconazole, clotrimazole, HIV and hepatitis C protease inhibitors, carbamazepine, phenytoin, phenobarbital and St. John's wort [1]. Cannabidiol can raise sirolimus levels, and the label says a dose reduction should be considered when the two are used together [1].

Grapefruit juice. The Rapamune label says grapefruit juice must not be taken with Rapamune or used to dilute it [1].

Cyclosporine raises sirolimus concentrations; the label says Rapamune is taken 4 hours after cyclosporine, and higher sirolimus doses are needed if cyclosporine is withdrawn [1].

Pregnancy. Sirolimus can cause fetal harm, and the label recommends highly effective contraception during treatment and for 12 weeks after the last dose [1]. The label found no clinically significant pharmacokinetic interaction with one specific contraceptive, norgestrel/ethinyl estradiol (Lo/Ovral), but says nothing about other pills [1].

Vaccines and fertility. The Rapamune label advises avoiding live vaccines and warns that azoospermia or oligospermia may occur [1].

Compounded product. The rapamycin used in PEARL was compounded [2]. Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before they are marketed [5].

Monitoring in trials. The Kraig trial tracked complete blood counts, a metabolic panel, HbA1c and oral glucose tolerance tests in older adults on 1 mg daily [3].

The longevity case, briefly

The mouse data are strong. Rapamycin fed to genetically heterogeneous mice from 600 days of age extended median and maximal lifespan, with increases of 14% for females and 9% for males based on age at 90% mortality, at three independent test sites; a separate study starting at 270 days also increased survival in both sexes [6]. Intermittent dosing has been tested too: 2 mg/kg every 5 days starting at 20 months extended lifespan in female C57BL/6J mice, and the authors describe that regimen as having less impact on glucose homeostasis and the immune system than chronic treatment [7].

The human data are short and small. PEARL ran 48 weeks, Kraig analyzed participants who completed at least 8 weeks, and neither measured lifespan [2][3]. A published opinion article argues that rapamycin's side effects are reversible and avoidable and should not rule out anti-aging use; that is one researcher's argument [8], not a trial result.